211 related articles for article (PubMed ID: 25981512)
1. Borderline pulmonary pressures in scleroderma - a 'pre-pulmonary arterial hypertension' condition?
Kovacs G; Olschewski H
Arthritis Res Ther; 2015 May; 17(1):123. PubMed ID: 25981512
[TBL] [Abstract][Full Text] [Related]
2. Evaluation and management of pulmonary hypertension in systemic sclerosis.
Preston IR; Hill NS
Curr Opin Rheumatol; 2003 Nov; 15(6):761-5. PubMed ID: 14569207
[TBL] [Abstract][Full Text] [Related]
3. Pulmonary arterial hypertension: an autoimmune disease?
Mouthon L; Guillevin L; Humbert M
Eur Respir J; 2005 Dec; 26(6):986-8. PubMed ID: 16319325
[No Abstract] [Full Text] [Related]
4. A comparison of nesiritide vs. epoprostenol in a patient with precapillary pulmonary hypertension due to scleroderma complicated by postcapillary pulmonary hypertension.
Zakir RM; Berkowitz RL; Saric M; Ashtyani H
Congest Heart Fail; 2005; 11(6):331-4. PubMed ID: 16330910
[TBL] [Abstract][Full Text] [Related]
5. [Pulmonary arterial hypertension in collagen disease: findings of the German Network for Systemic Scleroderma].
Halank M; Seyfarth HJ; Opitz C; Schmeisser A; Ewert R; Höffken G
Dtsch Med Wochenschr; 2007 Feb; 132(7):337; author reply 338. PubMed ID: 17286224
[No Abstract] [Full Text] [Related]
6. Systemic sclerosis patients with and without pulmonary arterial hypertension: a nailfold capillaroscopy study.
Riccieri V; Vasile M; Iannace N; Stefanantoni K; Sciarra I; Vizza CD; Badagliacca R; Poscia R; Papa S; Mezzapesa M; Nocioni M; Valesini G
Rheumatology (Oxford); 2013 Aug; 52(8):1525-8. PubMed ID: 23671125
[TBL] [Abstract][Full Text] [Related]
7. Incidence of pulmonary hypertension in patients with systemic sclerosis and no pulmonary symptoms: is annual echocardiographic screening necessary?
Foocharoen C; Mahakkanukrauh A; Pussadhamma B; Netwijitpan S; Suwannaroj S; Nanagara R
J Clin Rheumatol; 2014 Aug; 20(5):268-74. PubMed ID: 25036561
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of pulmonary arterial hypertension in an Australian scleroderma population: screening allows for earlier diagnosis.
Phung S; Strange G; Chung LP; Leong J; Dalton B; Roddy J; Deague J; Playford D; Musk M; Gabbay E
Intern Med J; 2009 Oct; 39(10):682-91. PubMed ID: 19220532
[TBL] [Abstract][Full Text] [Related]
9. [Pulmonary arterial hypertension in collagen disease: experiences of the German Network for Systemic Scleroderma].
Hunzelmann N; Riemekasten G
Dtsch Med Wochenschr; 2006 Dec; 131(49 Suppl 9):S325-7. PubMed ID: 17139598
[TBL] [Abstract][Full Text] [Related]
10. Systemic Sclerosis and Pulmonary Hypertension: The Great Masquerader.
Baratto C; Caravita S; Battista Perego G; Badano LP; Vachiéry JL; Parati G
Circ Heart Fail; 2021 Feb; 14(2):e007554. PubMed ID: 33504158
[No Abstract] [Full Text] [Related]
11. Predictors of isolated pulmonary hypertension in patients with systemic sclerosis and limited cutaneous involvement.
Steen V; Medsger TA
Arthritis Rheum; 2003 Feb; 48(2):516-22. PubMed ID: 12571862
[TBL] [Abstract][Full Text] [Related]
12. Borderline mean pulmonary artery pressure in patients with systemic sclerosis: transpulmonary gradient predicts risk of developing pulmonary hypertension.
Valerio CJ; Schreiber BE; Handler CE; Denton CP; Coghlan JG
Arthritis Rheum; 2013 Apr; 65(4):1074-84. PubMed ID: 23280155
[TBL] [Abstract][Full Text] [Related]
13. Pulmonary arterial hypertension: are we doing enough to identify systemic sclerosis patients at high risk of this rare condition?
Black C
Rheumatology (Oxford); 2005 Feb; 44(2):141-2. PubMed ID: 15681336
[No Abstract] [Full Text] [Related]
14. High incidence of pulmonary arterial hypertension in systemic sclerosis patients with anti-centriole autoantibodies.
Hamaguchi Y; Matsushita T; Hasegawa M; Ueda-Hayakawa I; Sato S; Takehara K; Fujimoto M
Mod Rheumatol; 2015 Sep; 25(5):798-801. PubMed ID: 24252018
[TBL] [Abstract][Full Text] [Related]
15. High prevalence of occult left heart disease in scleroderma-pulmonary hypertension.
Fox BD; Shimony A; Langleben D; Hirsch A; Rudski L; Schlesinger R; Eisenberg MJ; Joyal D; Hudson M; Boutet K; Serban A; Masetto A; Baron M
Eur Respir J; 2013 Oct; 42(4):1083-91. PubMed ID: 23258775
[TBL] [Abstract][Full Text] [Related]
16. Measures of systemic sclerosis (scleroderma): Health Assessment Questionnaire (HAQ) and Scleroderma HAQ (SHAQ), physician- and patient-rated global assessments, Symptom Burden Index (SBI), University of California, Los Angeles, Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT) 2.0, Baseline Dyspnea Index (BDI) and Transition Dyspnea Index (TDI) (Mahler's Index), Cambridge Pulmonary Hypertension Outcome Review (CAMPHOR), and Raynaud's Condition Score (RCS).
Pope J
Arthritis Care Res (Hoboken); 2011 Nov; 63 Suppl 11():S98-111. PubMed ID: 22588774
[No Abstract] [Full Text] [Related]
17. Determinants of exercise-induced pulmonary arterial hypertension in systemic sclerosis.
Voilliot D; Magne J; Dulgheru R; Kou S; Henri C; Laaraibi S; Sprynger M; Andre B; Pierard LA; Lancellotti P
Int J Cardiol; 2014 May; 173(3):373-9. PubMed ID: 24684997
[TBL] [Abstract][Full Text] [Related]
18. Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension.
Bhogal S; Mukherjee D; Banerjee S; Tan W; Paul TK
Curr Probl Cardiol; 2018 May; 43(5):191-216. PubMed ID: 29174585
[TBL] [Abstract][Full Text] [Related]
19. Scleroderma lung disease, variation in screening, diagnosis and treatment practices between rheumatologists and respiratory physicians.
Mangat P; Conron M; Gabbay E; Proudman SM;
Intern Med J; 2010 Jul; 40(7):494-502. PubMed ID: 19460060
[TBL] [Abstract][Full Text] [Related]
20. [Heart involvement and pulmonary arterial hypertension in patients with systemic sclerosis].
Cikes N
Reumatizam; 2010; 57(2):99-104. PubMed ID: 21875012
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
